Impression Acquires CBD Inhalers For Asthmatics

Impression Healthcare now has access to CBD pressurized metered-dose inhalers for distribution under the Special access scheme.

Impression Healthcare Limited (ASX: IHL), the developer of four unique medicinal cannabis products and owner of INCANNEXTM  cannabis oils, is pleased to announce that it has placed an initial order for 500 cannabidiol pressurized metered-dose inhalers from cGMP pharmaceutical manufacturer, Entourage Therapeutics LLC. In consideration for the placement of the initial order,

Entourage has granted IHL exclusivity over their product to be sold in Australia under the Special Access Scheme and to facilitate further discussions. The expected revenue to IHL from this order is expected to be circa $125,000.

IHL considers the purchase significant to the medicinal cannabis industry because there are currently no other suppliers in Australia. CBD inhalers are a preferable delivery application for patients with certain conditions currently being treated with CBD oils, potentially facilitating a significant competitive advantage to IHL. Those advantages include:

  • Inhaled CBD is delivered to the blood almost immediately. Maximum blood concentrations are achieved in around 10 minutes versus 1-4hrs for oral CBD
  • Bioavailability of inhaled CBD (<45%) is higher than oral CBD (<15%), meaning that lower dosages are required and more doses per unit volume are available to the patient
  • Side effects of inhaled CBD are minimised versus high-dosage oral CBD administration.

There is also an existing preliminary but promising body of research that the powerful anti-inflammatory properties*Notes 1,2,3 of CBD may be applied to treat lung inflammation, with inhalation devices delivering CBD to the site of inflammation.

Pre-clinical and in-human pilot studies support the potential for CBD in treating inflammation associated with pneumonia and acute lung injury ('ALI'), experienced by patients with Asthma and Chronic Obstructive Pulmonary Disease ('COPD'). It is clear that some patients with COVID-19 will develop pneumonia and ALI through inflammatory processes so IHL's medical advisory board will investigate the potential of CBD inhalers to assist with patient recovery.

PMDI's and the excipients used in them are an established method of drug delivery with a long history of safe use, primarily as asthma inhalers. They provide an extremely precise and effective method of delivering a target substance into a person's lungs and bloodstream, by avoiding what's known as "first pass metabolism" through the stomach and other digestive organs.

CEO and Managing Director, Mr Joel Latham, said; "We're delighted to be the first mover in offering a CBD inhalation administration device to the Australian medicinal cannabis market."

We predict that CBD inhalers will become the preferred delivery method for many patients.

CEO and Managing Director, Mr Joel Latham

"We're also excited at the prospect of opening new unregistered therapies for those suffering conditions associated with lung inflammation," Latham continued, "In addition to today's update, I'd like to take the opportunity to reiterate that we do not expect any material delays to our clinical programs for OSA and TBI resulting from current Governmental restrictions".

To learn more about Impression Healthcare, visit their company HQ here.

Subscribe Now
& Keep Up to Date

Get the latest pot stock recommendations, cannabis news
and industry updates straight to your inbox!

Louis O'Neill
Louis O'Neill

Louis is a writer based in Sydney with a focus on social and political issues. Having interviewed local politicians and entrepreneurs, Louis now focuses on cannabis culture, legislation & reform.

Leave a Reply

Your email address will not be published. Required fields are marked *